Cannabidiol is one of the most abundant active compounds in the cannabis plant, and unlike THC, it does not produce a high. That single distinction has driven enormous consumer and scientific interest over the past decade. CBD’s only fully approved pharmaceutical use is for certain rare childhood epilepsies, but research stretches across anxiety, pain, sleep, psychosis, cardiovascular health, and addiction. The story is more complicated than either the marketing hype or the skeptics suggest, because the compound’s behavior in the body creates real challenges for both researchers and consumers.
How the Body Handles CBD
One of the first things to understand about CBD is that your body is remarkably efficient at destroying it before it can do much of anything. When you swallow a CBD capsule or oil on an empty stomach, only about 6% of the dose reaches your bloodstream. The rest gets broken down by enzymes in the liver during what pharmacologists call first-pass metabolism, where roughly 70 to 75% of the absorbed dose is cleared before it ever circulates through the body.1PubMed. Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications On top of that, absorption through the gut wall is itself incomplete.
Eating a high-fat meal alongside CBD can increase bioavailability roughly fourfold, because fat encourages the compound to travel partly through the lymphatic system rather than going straight to the liver.2PubMed. The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations This is why the prescribing information for Epidiolex, the FDA-approved CBD medication, notes that it should be taken consistently with or without food, since toggling between the two creates unpredictable blood levels. After a large single oral dose in healthy adults, peak blood concentrations appeared four to five hours later, and the compound was rapidly converted into metabolites.3PubMed Central. Metabolism and liver toxicity of cannabidiol Over 90% of circulating CBD binds tightly to blood proteins, which further limits how much free compound is available to act on tissues.
The practical upshot: if you are taking an over-the-counter CBD product at a dose of, say, 25 milligrams, an extremely small fraction of that reaches your brain or other target organs. This is one reason clinical trials tend to use doses far higher than what most consumers take, and it raises real questions about whether the low-dose retail products popular in stores can deliver meaningful effects.
Epilepsy Is Where the Evidence Is Strongest
CBD earned its FDA approval by demonstrating clear benefits in children with severe epilepsy syndromes that had resisted other treatments. A systematic review and meta-analysis of clinical trials found that CBD roughly doubled or tripled the odds of achieving at least a 50% reduction in seizure frequency in patients with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex.4PubMed. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis The effect was significant both when CBD was used alone and when it was added to the antiseizure drug clobazam.
These are not marginal findings. For families dealing with dozens or hundreds of seizures per week, a treatment that doubles the chance of cutting that number in half is genuinely meaningful. That said, the doses used in epilepsy trials are high, often in the range of 10 to 25 milligrams per kilogram of body weight per day, which for an adult could mean over a thousand milligrams daily. These doses are orders of magnitude above what a typical consumer CBD oil delivers.
Anxiety and Stress
Anxiety is the reason most people reach for CBD, and the preclinical evidence is genuinely encouraging. A review of the animal and human literature found strong support for CBD reducing anxiety across several subtypes, including social anxiety, generalized anxiety, and panic, at least after a single dose.5PubMed Central. Cannabidiol as a Potential Treatment for Anxiety Disorders The same review noted a critical gap: very few studies had examined what happens with repeated daily dosing over weeks or months, which is how most consumers actually use CBD.
One well-known small study gave a single 400-milligram dose of CBD to people with social anxiety disorder, then scanned their brains. Compared to placebo, CBD significantly reduced self-reported anxiety and altered activity in brain regions involved in emotional processing.6PubMed. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report The findings align with broader evidence that CBD can influence brain function in ways relevant to anxiety, psychosis, and pain.7PubMed Central. Cannabidiol and brain function: current knowledge and future perspectives
Here is the honest picture, though: most of the positive anxiety data come from single-dose experiments in controlled settings. Whether taking 20 or 50 milligrams of a retail CBD oil every evening produces the same kind of relief is largely unproven. It might, but the clinical data have not caught up to the consumer behavior. People frequently report feeling calmer on CBD, and that is not nothing, but the gap between anecdotal experience and rigorous evidence remains wide for chronic anxiety use.
Pain and Inflammation
CBD has well-documented anti-inflammatory and antioxidant properties in laboratory settings.8PubMed Central. Antioxidative and Anti-Inflammatory Properties of Cannabidiol In animal models of arthritis, topical and transdermal CBD reduced joint swelling, immune cell infiltration, and markers of inflammation in a dose-dependent manner. Transdermal CBD gel applied to rats with arthritis significantly improved limb posture scores (a measure of spontaneous pain) and reduced inflammatory markers in the spinal cord and nerve roots.9PubMed Central. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis Another rat study found that topical CBD at the joint site decreased the movement of inflammatory white blood cells into the tissue, an effect that appeared to work partly through pain-sensing receptor channels rather than the classic cannabinoid receptors.10PubMed Central. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis
These animal results are promising, but human clinical trial evidence for CBD as a standalone pain treatment is still thin. The doses and delivery methods that work through rodent skin do not translate directly to humans, whose skin is thicker and less permeable. Many of the CBD creams and balms marketed for sore joints contain doses that have never been tested in controlled trials. That does not mean they are useless, but it does mean the confidence level for topical CBD pain relief in humans is lower than the marketing suggests.
Sleep
CBD’s relationship with sleep is more nuanced than the product labels imply. A review of the cannabinoid sleep literature found that CBD may hold promise for REM sleep behavior disorder, a condition where people physically act out their dreams, and for excessive daytime sleepiness.11PubMed. Cannabis, Cannabinoids, and Sleep: a Review of the Literature Preclinical work suggests CBD’s effects on sleep architecture depend on the dose and the brain region involved, with different doses potentially promoting wakefulness or sleepiness.12Quality in Sport. The Impact of Cannabidiol (CBD) on Sleep Quality: A Review of Mechanisms and Clinical Evidence
This dose-dependent behavior is worth emphasizing. At lower doses, CBD appears to have mild alerting properties in some studies, while higher doses seem to promote sedation. If you are taking a small dose before bed and not noticing much, this could be why. The anxiety-reducing effects of CBD may also indirectly help sleep by quieting the racing thoughts that keep people awake, even if CBD is not a sedative in the traditional sense. The evidence base for CBD as a primary sleep aid, though, remains preliminary compared to established treatments.
Psychosis
One of the more striking areas of CBD research is in schizophrenia. A multicenter randomized trial added CBD or placebo to existing antipsychotic medication in patients with schizophrenia. After six weeks, the CBD group showed lower levels of positive psychotic symptoms, such as hallucinations and delusions, and were more likely to be rated as improved by their clinicians.13PubMed. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial The researchers noted that CBD’s antipsychotic effects do not appear to involve blocking dopamine receptors the way conventional antipsychotics do, suggesting it could represent a genuinely new approach to treating the disorder.
This is a single trial, and the effect sizes were modest. But for a condition where existing medications carry heavy side-effect burdens including weight gain, metabolic problems, and movement disorders, even a modest additional benefit from a well-tolerated compound would matter. Larger confirmatory trials are still needed.
Cardiovascular Effects
Preclinical evidence suggests CBD can directly relax blood vessels, protect against heart damage from restricted blood flow, and reduce the cardiovascular response to stress.14PubMed Central. Is the cardiovascular system a therapeutic target for cannabidiol? A small randomized trial in healthy men tested these effects more directly. A single 600-milligram dose of CBD lowered resting mean arterial blood pressure by about 2 mmHg compared to placebo, and during stress tasks, systolic blood pressure dropped by about 6 mmHg in the CBD group. After seven days of dosing, participants showed improved artery flexibility and better endothelial function, both markers of cardiovascular health.15PubMed Central. The effects of acute and sustained cannabidiol dosing for seven days on the haemodynamics in healthy men: A randomised controlled trial
A 2 mmHg drop at rest is small, but population-level studies have shown that even modest reductions in blood pressure translate into meaningful decreases in stroke and heart disease risk across large groups. Whether CBD doses available in consumer products produce similar effects is unknown, since this trial used 600 milligrams per day.
Addiction and Craving
CBD has attracted interest as a potential tool for managing drug cravings, particularly in opioid use disorder. A double-blind randomized trial gave CBD or placebo to individuals who had previously used heroin but were currently abstinent. When exposed to drug-related cues such as images and videos of drug use, those who had taken CBD reported significantly less craving and anxiety than those on placebo. The effect persisted for at least a week after the last dose.16PubMed. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial Earlier preclinical work had shown CBD could inhibit cue-induced heroin-seeking behavior in animals for up to two weeks after the last dose.17PubMed Central. Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence
Separately, researchers have explored whether CBD could help ease opioid withdrawal symptoms, since the compound has properties that align with multiple withdrawal complaints including anxiety, nausea, pain, and inflammation.18PubMed Central. Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol This area remains early-stage, but the convergence of anti-anxiety, anti-inflammatory, and anti-craving effects in a single non-addictive compound is why addiction researchers are paying attention.
Liver Safety Is a Real Concern
This is something many CBD enthusiasts either do not know or prefer to ignore. A meta-analysis pooling data from clinical trials found that CBD use was associated with nearly six times the odds of liver enzyme elevations compared to placebo.19PubMed. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis About 7% of participants taking CBD in those trials had detectable liver enzyme rises, and about 3% had what qualified as drug-induced liver injury. The risk was concentrated among people taking high doses (1,000 milligrams per day or above) or using CBD alongside other antiepileptic drugs. No cases of liver enzyme elevation were reported in adults using doses below 300 milligrams per day, and no cases of severe liver injury were reported at any dose.
A 2025 randomized trial in healthy adults reinforced these concerns. Among participants receiving CBD, about 6% experienced liver enzyme levels more than three times the upper limit of normal after four weeks, while nobody in the placebo group did. A handful of participants had enzymes rise to more than five or even ten times the normal limit, and two of those also developed eosinophilia, a type of immune response that can signal a drug-allergy-like liver reaction.20JAMA Internal Medicine. Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial All cases resolved after stopping CBD.
For people taking typical consumer doses of 25 to 75 milligrams per day, the risk appears very low based on current data. But for anyone using higher doses, or combining CBD with medications that are processed by the same liver enzymes, periodic liver function checks are a reasonable precaution.
Drug Interactions Worth Knowing About
CBD is broken down by the same family of liver enzymes that metabolize a long list of common medications, and it can inhibit or alter the activity of some of those enzymes. This creates the potential for drug interactions that change how much of another medication ends up in your blood.21PubMed Central. Evaluation of potential drug-drug interactions with medical cannabis One specific example: CBD inhibits an enzyme responsible for converting the blood thinner clopidogrel into its active form, which could theoretically reduce the drug’s effectiveness and increase stroke risk.22PubMed. A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents
Other commonly used medications that share these enzyme pathways include certain antidepressants, antiseizure drugs, blood thinners, immunosuppressants, and some heart medications. If you take any prescription medication and are considering CBD at more than trace doses, a conversation with your pharmacist or prescriber is not optional. The interaction risk scales with CBD dose, so someone taking 10 milligrams from a gummy is in a different position than someone taking 300 milligrams from a tincture.
Product Quality Is a Mess
Because CBD products are regulated more like dietary supplements than drugs in most markets, what you see on the label and what is actually in the bottle frequently do not match. A large analysis of commercially available CBD products in the United States found pervasive low-level contamination with heavy metals and phthalates in edible products, and substantial discrepancies between the labeled CBD content and the amount actually measured.23PubMed. Heavy metal and phthalate contamination and labeling integrity in a large sample of US commercially available cannabidiol (CBD) products A similar study of UK products found that only about 38% contained CBD within 10% of what the label claimed, and over half contained measurable levels of THC or other controlled cannabinoids.24PubMed Central. An Analysis of Over-the-Counter Cannabidiol Products in the United Kingdom
This means that a product labeled as containing 25 milligrams per serving might actually contain 10 or 40. And for people who are drug-tested for work, the presence of unlabeled THC in many products is a genuine hazard. Third-party certificates of analysis from independent labs offer some protection, but even those vary in reliability. Until regulation catches up, consumers are essentially trusting brand reputation in a market that has very little accountability.
How CBD Gets From the Plant Into a Product
The cannabis plant does not actually produce CBD directly. It synthesizes an acidic precursor called CBDA, which converts to CBD through a heat-driven chemical reaction called decarboxylation. When cannabis is smoked, baked, or heated during extraction, CBDA loses a molecule of carbon dioxide and becomes CBD.25Journal of Plant Biochemistry and Biotechnology. Mechanism and kinetics of CBDA decarboxylation into CBD in hemp The conversion is not perfectly clean: if heating continues too long or at too high a temperature, CBD itself starts to degrade.26PubMed Central. Decarboxylation Study of Acidic Cannabinoids: A Novel Approach Using Ultra-High-Performance Supercritical Fluid Chromatography/Photodiode Array-Mass Spectrometry Some products deliberately preserve CBDA and market it as having its own distinct properties, though the evidence for that is thin.
You will often hear about the “entourage effect,” the idea that whole-plant cannabis extracts work better than purified CBD because terpenes, minor cannabinoids, and other plant compounds enhance CBD’s effects. The concept is plausible and has a pharmacological basis in synergy and bioenhancement, but the actual clinical evidence is mostly anecdotal and based on real-world experience rather than controlled trials. A review of the literature found that existing studies on the entourage effect rely on simplistic methods and produce contradictory findings.27PubMed Central. Decoding the Postulated Entourage Effect of Medicinal Cannabis: What It Is and What It Isn’t It may well turn out to be real, but “full-spectrum is always better than isolate” is a marketing claim that has outrun its evidence.
Immune and Gut Effects
CBD’s anti-inflammatory properties extend into the immune system in ways that are relevant to autoimmune conditions. In laboratory studies using immune cells involved in autoimmune attacks on nerve tissue, CBD suppressed the activity of a large number of pro-inflammatory genes, including those involved in key inflammatory signaling pathways like those driven by certain interleukins.28PubMed Central. Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells At the same time, CBD increased the activity of genes known to slow immune cell proliferation. Whether this translates into meaningful benefits for people with conditions like multiple sclerosis or rheumatoid arthritis remains to be demonstrated in large human trials.
Early research also suggests CBD can influence the gut microbiome. In a mouse study, CBD injections altered the microbial composition of the small intestine in a dose-dependent way, affecting bacterial groups associated with gut barrier integrity and immune function.29PubMed Central. Effect of intraperitoneal cannabidiol (CBD) injection on intestine microbiome profile in a mouse model Separately, mice fed a high-fat diet showed improved glucose tolerance and partial reversal of the gut microbiome disruption caused by the diet when given CBD.30PubMed Central. THC and CBD affect metabolic syndrome parameters including microbiome in mice fed high fat-cholesterol diet These are animal findings using injection or controlled oral dosing, so the relevance to someone eating a CBD gummy is speculative at best. But the gut-brain axis is a legitimate research frontier, and CBD’s interaction with it is being taken seriously.
Neuroprotection Research
CBD has drawn attention as a possible neuroprotective agent, particularly for neurodegenerative diseases like Alzheimer’s and Parkinson’s. The rationale is straightforward: neurodegeneration involves chronic inflammation, oxidative stress, and the accumulation of misfolded proteins, and CBD has shown activity against all three in laboratory settings.31PubMed. Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications A comprehensive review described CBD as a “potential prototype for neuroprotective drug development” based on these properties and its generally favorable safety profile.32PubMed Central. Cannabidiol for neurodegenerative disorders: A comprehensive review
The gap between “potential prototype” and “proven treatment” is vast, though. Almost all of the neuroprotection data come from cell cultures and animal models. Human neurodegenerative diseases unfold over decades, involve complex genetics, and have resisted countless compounds that looked promising in the lab. CBD may eventually contribute to treatments for these conditions, but right now that possibility is more about giving researchers a direction to explore than giving patients something to take. Anyone selling CBD as a brain-health supplement for dementia prevention is well ahead of what the science supports.